A resolution expressing the sense of the Senate that the Food and Drug Administration should encourage the use of abuse-deterrent formulations of drugs.

referredUnited States· United States Congress· EN

Introduced

15 April 2013

Last action

—

Status

Referred to the Committee on Health, Education, Labor, and Pensions. (text of measure as introduced: CR S2654)

Summary

Expresses the sense of the Senate that the Food and Drug Administration (FDA) should exercise its acknowledged authority to: (1) refuse to approve generic versions of non-abuse-deterrent opioid products that have been replaced in the market with abuse-deterrent formulations recognized by FDA as effective, and (2) require generic versions of abuse-deterrent opioid products to be formulated with comparable abuse-deterrent features.

This text is taken from the official record. PoliticalRepo does not editorialize.

Timeline

No timeline events have been ingested for this record yet.

Votes

No vote records are attached yet.

Versions

No version snapshots stored. Document URLs remain at the source.

Documents

3 official files

Introduced in Senate (text)
Introduced in Senate · EN · 15 April 2013
View Download Open at official source
Introduced in Senate (PDF)
Introduced in Senate · EN · 15 April 2013
View Download Open at official source
Introduced in Senate
summary · EN · 15 April 2013
Open at official source

Related records

No cross-record relationships stored yet.

Sources

PoliticalRepo is an index and interpretation layer, not the authoritative legal source.

Official source: https://www.congress.gov/bill/113th-congress/senate-resolution/97
Open data entity: https://api.congress.gov/v3/bill/113/sres/97